Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany

PURPOSE. Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2‐positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivot...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Oncologist
Κύριοι συγγραφείς: Dall, Peter, Koch, Thorsten, Göhler, Thomas, Selbach, Johannes, Ammon, Andreas, Eggert, Jochen, Gazawi, Nidal, Rezek, Daniela, Wischnik, Arthur, Hielscher, Carsten, Keitel, Stella, Cirrincione, Ursula, Hinke, Axel, Feisel‐Schwickardi, Gabriele
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: AlphaMed Press 2017
Θέματα:
Breast Cancer
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330700/
https://ncbi.nlm.nih.gov/pubmed/28174294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0193
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια